Drug Patents Expiring in 2040
1. Drug name - AIRDUO DIGIHALER
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11173259 | TEVA PHARM | Drug delivery device with electronics and power management |
Jul, 2040
(17 years from now) | |
Drugs and Companies using FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE ingredient
Treatment: NA
Dosage: POWDER;INHALATION
| Strength | Dosage | Availability |
|---|---|---|
| 0.055MG/INH;EQ 0.014MG BASE/INH | POWDER;INHALATION | Prescription |
| 0.113MG/INH;EQ 0.014MG BASE/INH | POWDER;INHALATION | Prescription |
| 0.232MG/INH;EQ 0.014MG BASE/INH | POWDER;INHALATION | Prescription |
2. Drug name - AMELUZ
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11235169 | BIOFRONTERA | Illumination device for photodynamic therapy, method for treating a skin disease and method for operating an illumination device |
Oct, 2040
(18 years from now) | |
Drugs and Companies using AMINOLEVULINIC ACID HYDROCHLORIDE ingredient
Treatment: Topical lesion-directed and field-directed treatment of actinic keratosis of the face and scalp with photodynamic therapy by positioning an illumination device in an appropriate distance and illuminating the treatment area with narrowband red light
Dosage: GEL;TOPICAL
| Strength | Dosage | Availability |
|---|---|---|
| 10% | GEL;TOPICAL | Prescription |
3. Drug name - ARMONAIR DIGIHALER
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11173259 | TEVA PHARM | Drug delivery device with electronics and power management |
Jul, 2040
(17 years from now) | |
| Strength | Dosage | Availability |
|---|---|---|
| 0.055MG/INH | POWDER;INHALATION | Discontinued |
| 0.113MG/INH | POWDER;INHALATION | Discontinued |
| 0.232MG/INH | POWDER;INHALATION | Discontinued |
| 0.03MG/INH | POWDER;INHALATION | Discontinued |
4. Drug name - EMERPHED
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11090278 | NEXUS PHARMS | Compositions comprising ephedrine or an ephedrine salt and methods of making and using same |
May, 2040
(17 years from now) | |
| US11241400 | NEXUS PHARMS | Compositions comprising ephedrine or an ephedrine salt and methods of making and using same |
May, 2040
(17 years from now) | |
Drugs and Companies using EPHEDRINE SULFATE ingredient
Treatment: Use of ephedrine sulfate for treating hypotension
Dosage: SOLUTION;INTRAVENOUS
| Strength | Dosage | Availability |
|---|---|---|
| 50MG/10ML (5MG/ML) | SOLUTION;INTRAVENOUS | Prescription |
5. Drug name - EPHEDRINE SULFATE
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10869845 | ENDO VENTURES | Ephedrine compositions and methods |
Jan, 2040
(17 years from now) | |
| Strength | Dosage | Availability |
|---|---|---|
| 50MG/10ML (5MG/ML) | SOLUTION;INTRAVENOUS | Prescription |
6. Drug name - FARXIGA
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10973836 | ASTRAZENECA AB | Methods of treating heart failure with reduced ejection fraction |
Mar, 2040
(17 years from now) | |
Drugs and Companies using DAPAGLIFLOZIN ingredient
Treatment: Reduction of the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure with reduced ejection fraction and without type ii diabetes
Dosage: TABLET;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 5MG | TABLET;ORAL | Prescription |
| 10MG | TABLET;ORAL | Prescription |
7. Drug name - HETLIOZ LQ
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11202770 | VANDA PHARMS INC | Liquid tasimelteon formulations and methods of use thereof |
Dec, 2040
(18 years from now) | |
| Strength | Dosage | Availability |
|---|---|---|
| 4MG/ML | SUSPENSION;ORAL | Prescription |
8. Drug name - INGREZZA
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10940141 | NEUROCRINE | Methods for the administration of certain VMAT2 inhibitors |
Aug, 2040
(17 years from now) | |
Drugs and Companies using VALBENAZINE TOSYLATE ingredient
Treatment: Treatment of tardive dyskinesia
Dosage: CAPSULE;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| EQ 40MG BASE | CAPSULE;ORAL | Prescription |
| EQ 60MG BASE | CAPSULE;ORAL | Prescription |
| EQ 80MG BASE | CAPSULE;ORAL | Prescription |
9. Drug name - LIVMARLI
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11229647 | MIRUM | Methods for treating cholestasis |
Feb, 2040
(17 years from now) | |
Drugs and Companies using MARALIXIBAT CHLORIDE ingredient
Treatment: Treatment of cholestatic pruritus in patients with alagille syndrome (algs)
Dosage: SOLUTION;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| EQ 9.5MG BASE/ML | SOLUTION;ORAL | Prescription |
10. Drug name - LUMAKRAS
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US11236091 | AMGEN INC | Solid state forms |
May, 2040
(17 years from now) | |
| Strength | Dosage | Availability |
|---|---|---|
| 120MG | TABLET;ORAL | Prescription |
11. Drug name - MYCAPSSA
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11141457 | AMRYT | Oral octreotide therapy and contraceptive methods |
Dec, 2040
(18 years from now) | |
Drugs and Companies using OCTREOTIDE ACETATE ingredient
Treatment: Use of oral octreotide for long-term maintenance treatment in acromegaly patients while avoiding concomitant administration of levonorgestrel
Dosage: CAPSULE, DELAYED RELEASE;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| EQ 20MG BASE | CAPSULE, DELAYED RELEASE;ORAL | Prescription |
12. Drug name - PROAIR DIGIHALER
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11173259 | TEVA BRANDED PHARM | Drug delivery device with electronics and power management |
Jul, 2040
(17 years from now) | |
Drugs and Companies using ALBUTEROL SULFATE ingredient
Treatment: NA
Dosage: POWDER, METERED;INHALATION
| Strength | Dosage | Availability |
|---|---|---|
| EQ 0.09MG BASE/INH | POWDER, METERED;INHALATION | Prescription |
13. Drug name - QDOLO
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11103452 | ATHENA | Tramadol hydrochloride solution |
Sep, 2040
(17 years from now) | |
Drugs and Companies using TRAMADOL HYDROCHLORIDE ingredient
Treatment: Management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate
Dosage: SOLUTION;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 5MG/ML | SOLUTION;ORAL | Prescription |
14. Drug name - QINLOCK
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10966966 | DECIPHERA PHARMS | Methods of treating gastrointestinal stromal tumors |
Aug, 2040
(17 years from now) | |
| US11185535 | DECIPHERA PHARMS | Amorphous kinase inhibitor formulations and methods of use thereof |
Dec, 2040
(18 years from now) | |
Drugs and Companies using RIPRETINIB ingredient
Treatment: Treatment of advanced gastrointestinal stromal tumor in patients having progressed from a first line administration of imatinib, a second line administration of sunitinib, and a third line administration of regorafenib
Dosage: TABLET;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 50MG | TABLET;ORAL | Prescription |
15. Drug name - RECORLEV
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11020393 | STRONGBRIDGE | Methods of treating disease with levoketoconazole |
Mar, 2040
(17 years from now) | |
Drugs and Companies using LEVOKETOCONAZOLE ingredient
Treatment: During levoketoconazole dosage titration for the treatment of cushing's syndrome in patients who concomitantly use metformin, monitoring glycemia, kidney function and vitamin b-12 and adjusting dosage of metformin as needed
Dosage: TABLET;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 150MG | TABLET;ORAL | Prescription |
16. Drug name - SUNOSI
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10940133 | JAZZ | Methods of providing solriamfetol therapy to subjects with impaired renal function |
Mar, 2040
(17 years from now) | |
Drugs and Companies using SOLRIAMFETOL HYDROCHLORIDE ingredient
Treatment: Treatment of excessive daytime sleepiness associated with obstructive sleep apnea (osa) in a patient with moderate renal impairment
Dosage: TABLET;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| EQ 75MG BASE | TABLET;ORAL | Prescription |
| EQ 150MG BASE | TABLET;ORAL | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.